 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
 |
|
|
|
|
|
|
|
|
Subscribe to Insight Genetics News
QIAGEN gains rights to genomic biomarkers for lung, brain and other
cancers to expand its pipeline of companion diagnostics
Insight Genetics has entered into a strategic co-development partnership and licensing agreement with QIAGEN for a genetic test covering the ALK (anaplastic lymphoma kinase) biomarker, a promising target for a novel class of lung cancer drugs.
January 10, 2012 | Read More
Insight Genetics Receives Contract from National Cancer Institute
Cancer diagnostics firm Insight Genetics today announced that it has received a $193,000 Small Business Innovation Research contract from the National Cancer Institute (NCI) to develop a companion diagnostic test for drugs targeting mutations and fusions of anaplastic lymphoma kinase (ALK). The test, Insight ALK Resistance™, is being developed to meet a growing challenge within personalized cancer care: the development of tumor resistance to a prescribed drug.
October 5, 2011 | View Release (PDF)
Clinical Lab Products - Unique as a Fingerprint: Update on how some companies
are embracing personalized medicine in oncology testing
We may have expected broader, more quickly realized applications following early successes in personalized medicine, but widespread benefits are materializing. Personalized medicine has grown more rapidly in the area of oncology than in any other large disease category, mostly due to greater scientific study of the role of specific genetic traits in cancer. Companion diagnostics are generating increasing development in personalized cancer care, offering the promise of matching a cancer therapy to a person’s disease at the molecular level.
September 3, 2011 | Read More
Nashville Medical News - Testing, Testing: Insight Genetics Develops Test for ALK
A spinout of Genetic Assays, a clinical diagnostics services firm, Insight Genetics was established in late 2007 to pursue molecular testing, particularly for cancer. Initially housed in the CET Life Sciences Center, one of the company’s early advisors has been Stephan W. Morris, MD, an oncologist in the Department of Pathology at St. Jude Children’s Research Hospital, who is internationally recognized as the discoverer and a leading researcher on anaplastic lymphoma kinase (ALK).
September 2011 | Read More
Clinical Lab Products - Insight Genetics: Meeting the Need for Advanced ALK Diagnostics
The field of molecular diagnostics is becoming increasingly important across health care. Scientific discoveries related to key biomarkers combined with advances in molecular testing have enhanced our ability to diagnose, manage, and treat a range of medical conditions. Perhaps no clinical area has been more altered by molecular diagnostics than oncology.
April 2011 | Read More
Insight Genetics Presents Data at 2011 American Association of
Cancer Research Annual Meeting
Insight Genetics, Inc. presented a poster titled, “Insight ALK Screen™, a highly sensitive and specific RT-qPCR first-line screening assay for the comprehensive detection of all oncogenic anaplastic lymphoma kinase (ALK) fusions.” Authors included David Hout, John Handshoe and Josh Nickols of Insight Genetics, Stephan W. Morris and Liquan Xue of St. Jude Children’s Research Hospital, and Derek Bouman, Kameron Schmidt, Kenneth Bloom and Douglas Ross of Clarient/GE Healthcare, Inc.
March 31, 2011 | For more information or to receive a copy of the poster, please contact us.
Insight Genetics Receives Contract from National Cancer Institute
to Develop New Lung Cancer Test
Insight Genetics today announced that it has entered into an exclusive worldwide licensing agreement with St. Jude Children’s Research Hospital that will help the company create a new diagnostic test that will assist physicians in monitoring cancer patients and make more effective treatment selection decisions.
December 14, 2010 | View Release (PDF)
Insight Genetics Awarded Qualifying Therapeutic Discovery Program Grant
Insight Genetics today announced that it has been awarded a $244,479 grant to advance the development of novel molecular diagnostic tests for cancer. The grant was awarded by the Internal Revenue Service and the U.S. Department of Health and Human Services as part of the Qualifying Therapeutic Discovery Project Program (QTDP), which was established under the Patient Protection and Affordable Care Act of 2010.
November 16, 2010 | View Release (PDF)
Insight Genetics Receives Contract from National Cancer Institute
to Develop New Lung Cancer Test
Insight Genetics today announced that it has been awarded a $200,000 Phase I Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI) to develop a new test for lung cancer patients. The contract was awarded as part of a solicitation titled, “Companion Diagnostics: Predictive and Prognostic Tests Enabling Personalized Medicine in Cancer Therapy.”
November 9, 2010 | View Release (PDF)
